Barclays PLC Reduces Stake in Enhabit, Inc. (NYSE:EHAB)

Barclays PLC reduced its holdings in Enhabit, Inc. (NYSE:EHAB) by 74.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,321 shares of the company’s stock after selling 234,757 shares during the period. Barclays PLC owned about 0.16% of Enhabit worth $627,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. WINTON GROUP Ltd purchased a new stake in Enhabit in the second quarter valued at $955,000. Marshall Wace LLP acquired a new position in shares of Enhabit in the 2nd quarter valued at about $1,941,000. Systematic Financial Management LP boosted its stake in shares of Enhabit by 12.2% in the third quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock worth $14,522,000 after buying an additional 199,235 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Enhabit during the third quarter worth about $215,000. Finally, AREX Capital Management LP raised its position in Enhabit by 2.5% during the second quarter. AREX Capital Management LP now owns 2,472,662 shares of the company’s stock valued at $22,056,000 after acquiring an additional 59,353 shares in the last quarter.

Enhabit Stock Up 1.6 %

EHAB opened at $7.81 on Thursday. The company has a market cap of $392.72 million, a PE ratio of -3.37 and a beta of 1.89. Enhabit, Inc. has a twelve month low of $6.85 and a twelve month high of $11.74. The company has a 50-day moving average price of $7.72 and a 200 day moving average price of $8.18. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85.

Enhabit (NYSE:EHAB) last released its earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. The firm had revenue of $253.60 million during the quarter, compared to analysts’ expectations of $261.69 million. During the same quarter last year, the business earned $0.03 EPS. Sell-side analysts expect that Enhabit, Inc. will post 0.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Stuart M. Mcguigan purchased 15,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This trade represents a 47.15 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bolton acquired 4,000 shares of Enhabit stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the transaction, the director now owns 98,144 shares of the company’s stock, valued at $852,871.36. This represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on EHAB. Leerink Partners reissued a “market perform” rating and set a $8.00 target price (down from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. Jefferies Financial Group raised Enhabit from a “hold” rating to a “buy” rating and raised their price objective for the company from $8.25 to $9.50 in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Enhabit has an average rating of “Hold” and an average price target of $8.75.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.